Comparative Pharmacology
Head-to-head clinical analysis: TRULICITY versus YEZTUGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRULICITY versus YEZTUGO.
TRULICITY vs YEZTUGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist. Increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Yeztugo (tugofinitib) is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1-4. It binds to the ATP-binding pocket of FGFR kinases, blocking downstream signaling pathways (RAS-MAPK, PI3K-AKT, STAT) involved in cell proliferation and survival.
1.5 mg subcutaneously once weekly, with or without food.
YEZTUGO is not an approved drug. No standard dosing available.
None Documented
None Documented
Terminal elimination half-life approximately 5 days (112–120 hours) after subcutaneous administration, supporting once-weekly dosing.
12-15 hours in healthy adults; prolonged to 24-30 hours in moderate hepatic impairment.
Renal: negligible (intact peptide not excreted in urine); Biliary/fecal: peptide backbone catabolized via proteolysis, with amino acids recycled; no biliary excretion of intact drug.
Primarily renal (>90% unchanged) with 5-10% biliary/fecal elimination.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist